Arvinas Eyes Parkinson’s LRRK2 Readout, Five Phase 1 Programs by Year-End
Arvinas has four Phase 1 PROTAC programs in clinic and expects a fifth by year-end, with Parkinson’s LRRK2 degrader Phase 1 readout due in weeks. Oncology updates include KRAS G12D degrader ARV-806 data expected in 2026, early BCL6 degrader responses with H2 readout, and a June 5 PDUFA decision on breast-cancer candidate vepdegestrant.
1. Phase 1 Pipeline Expansion
Arvinas has four PROTAC-based Phase 1 programs in the clinic and expects a fifth by year-end after initiating its fourth androgen receptor degrader. The company highlights its pivotal trial–proven protein-degradation platform and says it has capital to drive programs to key inflection points.
2. Neurodegeneration Readout
The LRRK2 degrader ARV-102 showed dose-dependent cerebrospinal fluid exposure and LRRK2 reduction in healthy volunteers, with Parkinson’s patient Phase 1 data due in weeks. Plans include confirming pathway engagement in diseased patients and moving into progressive supranuclear palsy studies pending regulatory clearance.
3. Oncology Milestones
Enrollment for KRAS G12D degrader ARV-806 is complete with first clinical data expected in 2026, while the BCL6 degrader ARV-393 has demonstrated early responses ahead of a second-half first-in-human readout. Breast-cancer degrader vepdegestrant faces a June 5 PDUFA decision and is seeking a commercialization partner.
4. Androgen Receptor Degraders
ARV-027, the third mutant androgen receptor degrader targeting spinal and bulbar muscular atrophy, began dosing in healthy volunteers after preclinical models showed muscle rescue and prolonged survival. A collaboration with Novartis on luxdegalutamide continues advancing multiple combination trials in prostate cancer.